Dapagliflozin attenuates cardiomyocyte hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgag120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Liying Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510440, P.R. China. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, Ferroptosis, NF-E2-Related Factor 2, Myocytes, Cardiac. Die Arbeit nennt 73 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Bureau, Research Project of Guangdong Yiyang Healthcare Charity Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Objectives
Myocardial hypertrophy is a common pathological process in various cardiovascular diseases and may ultimately lead to heart failure. As a sodium-glucose cotransporter 2 inhibitor, dapagliflozin (DAPA) has been demonstrated to be cardioprotective, in addition to its hypoglycemic effect. However, the precise mechanism of DAPA in myocardial hypertrophy remains unclear.
Methods
H9C2 rat cardiomyoblast cell line were subjected to isoproterenol (ISO)-induced hypertrophy and erastin-induced ferroptosis, and treated with DAPA, ferrostatin-1, KEAP1 activator K67, or inhibitor ML334. Hypertrophic markers and cell surface area were assessed by quantitative real-time polymerase chain reaction and rhodamine-phalloidin staining. Ferroptosis was evaluated by measuring glutathione (GSH), malondialdehyde, reactive oxygen species, lipid peroxidation, intracellular ferrous iron, and mitochondrial membrane potential. Protein expression of KEAP1, NRF2, solute carrier family 7 member 11, and GSH peroxidase 4 was determined by western blot. Key findings DAPA attenuated ISO-induced cardiomyocyte hypertrophy and suppressed ferroptosis by inhibiting KEAP1 to activate NRF2, upregulating downstream targets. GSH peroxidase 4 knockdown abolished DAPA’s protective effects. KEAP1 reactivation with K67 reversed DAPA-mediated cardioprotection, whereas KEAP1 inhibition with ML334 recapitulated it.
Conclusions
DAPA exerts a protective role in myocardial hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway, providing novel insights into the potential mechanism and application of DAPA on cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510440, P.R. China.
- Department of Pharmacy, The Sixth Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, Guangdong 510655, P.R. China.
- Department of Pharmacy, The Eighth Affiliated Hospital of Southern Medical University, Foshan, Guangdong 528308, P.R. China.
- School of Pharmacy, Guangzhou Health Science College, Guangzhou, Guangdong 510450, P.R. China.
ORCID-Profile: Yanfang Chen
Förderung
- Guangzhou Municipal Science and Technology Bureau
- Research Project of Guangdong Yiyang Healthcare Charity Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- Science and Technology Project of Guangzhou
Zitieren
APA
Liang, L., Wang, Q., Zhen, H., Chen, X., He, Q., Wang, M., Hong, Y., Zeng, S., Li, X., & Chen, Y. (2026). Dapagliflozin attenuates cardiomyocyte hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag120
Vancouver
Liang L, Wang Q, Zhen H, Chen X, He Q, Wang M, et al. Dapagliflozin attenuates cardiomyocyte hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag120
BibTeX
@article{Liang2026,
author = {Liang, Liying and Wang, Qiujuan and Zhen, Honghui and Chen, Xi and He, Qin and Wang, Mingli and Hong, Ye and Zeng, Siyu and Li, Xiaoyan and Chen, Yanfang},
title = {Dapagliflozin attenuates cardiomyocyte hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag120}
}
EUVIMED